IFN-γ priming up-regulates IFN-stimulated gene factor 3 (ISGF3) components, augmenting responsiveness of IFN-resistant melanoma cells to type I IFNs

Journal of Immunology

Volumn 160, Issue 11, 1998, Pages 5475-5484

  Wong, Lee H ^a   Hatzinisiriou, Irene ^a   Devenish, Rodney J ^a   Ralph, Stephen J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHASE; ALPHA2A INTERFERON; DNA BINDING PROTEIN; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON STIMULATED GENE FACTOR 3; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA BINDING; HUMAN; HUMAN CELL; IMMUNOREGULATION; MELANOMA; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION;

ADJUVANTS, IMMUNOLOGIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON ALFA-2A; INTERFERON TYPE I; INTERFERON TYPE II; INTERFERON-STIMULATED GENE FACTOR 3; INTERFERON-STIMULATED GENE FACTOR 3, GAMMA SUBUNIT; MELANOMA; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0032102991     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Isaac, A., and J. Lindermann. 1957. Virus interference: the interferons. Proc. R. Soc. Lond. B. Biol. Sci. 147:258.
2. Pestka, S., J. A Langer, K. C. Koon, and C. E. Samuel. 1987. Interferons and their actions. Annu. Rev. Biochem. 56:727.
3. Colamonici, O. R., and L. C. Platanias. 1992. Interferon-α induces rapid tyrosine phosphorylation of the a subunit of its receptor. J. Biol. Chem. 267:2502.
4. Novick, D., B. Cohen, and M. Rubenstein. 1994. The human interferon-α and -β receptor: characterization and molecular cloning. Cell 77:391.
5. Darnell, J. E., Jr., I. M. Kerr, and G. R. Stark. 1994. JAK-STAT pathways and transcriptional activation to interferons and other extracellular signalling proteins. Science 264:1415.
6. Shuai, K. 1994. Interferon-activated signal transduction to the nucleus. Curr. Opin. Cell Biol. 253.
7. Wilks, A. F., and A. G. Harpur. 1994. Cytokine signal transduction and the JAK family of protein tyrosine kinases. Bioessays 16:313.
8. Aguet, M., and G. Merlin. 1987. Purification of human Interferon-γ receptors by sequential affinity chromatography on immobilized monoclonal anti-receptor antibodies and human interferon-γ. J. Exp. Med. 165:988.
9. Muller, M., C. Laxton, J. Briscoe, C. Schindler, T. Improta, J. E. Darnell, Jr., G. R. Stark, and I. M. Kerr. 1993. Complementation of a mutant cell line: central role the 91-kDa polypeptide of ISGF3 in the interferon-α and -γ signal transduction pathway. EMBO J. 12:4221.
10. Watling, D., D. Gushin, M. Muller, O. Silvennoinen, B. A. Witthunn, F. W. Quelle, N. C. Rogers, C. Schindler, G. R. Stark, and I. M. Kerr. 1993. Complementation of a mutant cell line defective in the interferon-γ signal transduction pathway by the protein tyrosine kinase JAK-2. Nature 366:166.
11. Shuai., K., C. M. Horvath, L. H. Tsai-Huang, S. Qureshi, D. Cowburn, and J. E. Darnell, Jr. 1994. Interferon activation of transcription factor STAT91 involves dimerization through SH2-phosphotyrosyl peptide interaction. Cell 76:821.
12. Takaku, F. 1994. Clinical application of cytokines for cancer treatment. Oncology 51:123.
13. Agarwala, S. S., and J. M. Kirkwood. 1994. Interferons in the therapy of solid tumors. Oncology 51:129.
14. Reintgen, D., C. M. Balch, J. Kirkwood, and M. Ross. 1997. Recent advances in the care of the patient with malignant melanoma. Ann. Surg. 225:1.
15. Ralph, S. J., B. D. Wines, M. J. Payne, D. Grubb, I. Hatzinisiriou, and R. J. Devenish. 1994. Resistance of melanoma cell lines to interferons correlates with the reduced levels of interferon-induced changes in tyrosine-phosphorylated cellular proteins. J. Immunol. 154:2248.
16. Wong, L. H., K. G. Krauer, M. J. Estcourt, I. Hatzinisiriou, P. Hersey, N. D. Tam, S. Edmondson, R. J. Devenish, and S. J. Ralph. 1997. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2 and p48-ISGF3γ. J Biol. Chem. 272:28779.
17. Levy, D. E., D. S. Kessler, R. Pine, and J. E. Darnell, Jr. 1989. Cytoplasmic activation of ISGF3, the positive regulator of interferon-α-stimulated transcription, reconstituted in vitro. Genes Dev. 3:1362.
18. Levy, D. E., D. J. Lew, T. Decker, D. S. Kessler, and J. E. Darnell, Jr. 1990. Synergistic interaction between interferon-α and interferon-γ through induced synthesis of the one subunit of the transcription factor ISGF3. EMBO J. 9:1105.
19. Gao, P-Q., S. H. Sims, D. C. Chang, and A. B. Deisseroth. 1993. Interferon-γ-priming effects in activation and deactivation of ISGF3 in K562 cells. J. Biol. Chem. 268:12380.
20. Improta, T., R. Pine, and L. M. Pfeffer. 1992. Interferon-γ potentiates the antiviral activity and the expression of interferon-stimulated genes induced by interferon-α in U937 cells. J. Interferon Res. 12:87.
21. Xu, B., D. Grander, O. Sangfelt, and S. Einhorn. 1994. Primary leukemia cells resistant to Interferon-α in vitro are defective in the activation of the DNA-binding factor interferon-stimulated gene factor 3. Blood 84:1942.
22. Lehtonen, A., S. Matikainen, and I. Julkunen. 1997. Interferons up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages. J. Immunol. 159:794.
23. Whitehead, R. H., and J. H. Little. 1973. In Pigment Cells, Vol. 1. V. J. McGovern and P. Russell, eds. S. Karger, Basel, pp. 382-389.
24. Luttrell, D. K., A. Lee, T. J. Lansing, R. M. Crosby, K. D. Jung, D. Willard, M. Luther, M. Rodriguez, J. Berman, and T. M. Gilmer. 1994. Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proc. Natl. Acad. Sci. USA 91:83.
25. Boyd, A. W., S. O., Wawryk, G. F., Burns, and J. V. Fecondo. 1988. Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms. Proc. Natl. Acad. Sci. USA 85:3095.
26. Levy, D., A. Larner, A. Chaudhuri, L. E. Babiss, and J. E. Darnell, Jr. 1986. Interferon-stimulaled transcription: isolation of an inducible gene and identification of its regulatory region. Proc. Natl. Acad. Sci. USA 83:8929.
27. Gough, N. 1987. Rapid and quantitative preparation of cytoplasmic RNA from small numbers of cells. Anal. Biol. 173:93.
28. Sambrook, J., E. F. Fitch, and T. Maniatis. 1982. Molecular Cloning, A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
29. Piechaczyk, M., J. M. Blanchard, L. Marty, C. Dani, F. Panabieres, S. El. Sabouty, P. Fort, and P. Jeanteur. 1984. Post-transcriptional regulation of glyceraldehyde-3-phosphate dehydrogenase gene expression in rat tissues. Nucleic Acids Res. 12:6951.
30. Hassanain, H. H., W. Dai, and S. L. Gupta. 1993. Enhanced gel mobility shift assay for DNA binding factors. Anal. Biochem. 213:162.
31. Johns, T. G., I. R. Mackay, K. A. Callister, P. J. Hertzog, R. J. Devenish, and A. W. Linnane. 1992. Antiproliferative potencies of interferons on melanoma cell lines and xenografts. J. Natl. Cancer Inst. 84:1185.
32. Wines, B. D., C. C. Choe, I. Hatzinisiriou, R. J. Devenish, A. W. Linnane, and S. J. Ralph. 1993. A colourimetric dye to detect anti-viral activity of interferons: sensitivity for measuring cellular responsiveness to interferons. Biochem. Mol. Biol. Int. 31:1111.
33. Baglioni, C., and P. A. Maroney. 1980. Mechanism of action of human interferons: induction of 2,5-oligo(a) polymerase. J. Biol. Chem. 255:8390.
34. Broeze, R. J., J. P. Daugherty, J. Pichon, B. M. Jayaram, and P. Lengyel. 1981. Studies with pure mouse Ehrlich ascites tumor interferons-α and -β: patterns of induction of 2-5 A synthetase and a dsRNA dependent protein kinase in mouse cells and human cells. J. Interferon Res. 1:191.
35. Verhaegen-Lewalle, M., T. Kuwata, Z.-X. Zhung, E. De Clercq, K. Cantell, and J. U. Content. 1982. 2-5 A synthetase activity induced by interferon-α, -β and -γ in human cell lines differing in their sensitivity to the anticellular and antiviral activities of these interferons. Virology 117:425.
36. Nistico, P., R. Tecce, P. Giacomini, A. Cavallari, I. D'Agnano, P. B. Fisher, and P. G. Natali. 1990. Effect of recombinant human leukocyte, fibroblast, and immune interferons on the expression of class I and II major histocompatibility complex and invariant cells. Cancer Res. 50:7422.
37. Allison, J. P., A. A. Hurwitz, and D. R. Leach. 1995. Manipulation of costimulatory signals to enhance antitumor T cell responses. Curr. Opin. Immunol. 7:682.
38. Galea-Lauri, J., F. Farzaneh, and J. Gaken. 1996. Novel costimulators in the immune gene tharapy of cancer. Cancer Gene Ther. 3:202.
39. Kolla, V., D. J. Lindner, X. Weihua, E. C. Borden, and D. V. Kalvakolanu. 1996. Modulation of interferon-inducible gene expression by retinoic acid: up-regulation of STAT1 protein in IFN-unresponsive cells. J. Biol. Chem. 271:10508.
40. Matikainen, S., T. Ronni, A. Lehtonen, T. Sareneva, K. Melen, S. Nordling, D. E. Levy, and I. Julkunen. 1997. Retinoic acid induces signal transducer and activator of transcription (STAT)1, STAT2, and p48 expression in myeloid leukemia cells and enhances their responsiveness to interferons. Cell Growth Differ. 8:687.
41. Justesen, J., and K. Berg. 1986. Synergistic effects of huIFN-γ on 2′,5′-oligoadenylate synthetase induction by huIFN-α. 1986. J. Interferon Res. 6:445.
42. Germain, R., D. Margulies. 1993. The biochemistry and cell biology of antigen presentation. Annu. Rev. Immunol. 11:403.
43. Hui, K., F. Grosveld, and H. Festenstein. 1984. Rejection of transplantable AKR leukemic cells following MHC DNA-mediated cell transformation. Nature 311:750.
44. Tanaka, K., K. Isselbacher, G. Khoury, and G. Jay. 1985. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 228:26.
45. Wallich, R., N. Bulbic, G. Hammerling, S. Katzav, S. Segal, and S. Feldman. 1985. Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315:301.
46. Plaskin, D., C. Gelber, M. Feldman, and L. Eisenbach. 1988. Reversal of metastatic phenotype in Lewis lung carcinoma cells following transfection with syngenic H-2Kb gene. Proc. Natl. Acad. Sci. USA 85:4463.
47. Chen, L., P. McGowan, S. Ashe, J. Johnston, and Y. Li. 1994. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523.
48. Baskar, S., S. Ostrand-Rosenberg, N. Nabavi, L. M. Nadler, G. J. Freeman, L. H. Glimcher. 1993. Constitutive expression of B7 restores immunogenicity of tumor cells, expressing truncated major compatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 90:5687.
49. Townsend, S., and J. P. Allison. 1993. Tumor rejection after direct costimulation by B7-transfected melanoma cells. Science 259:368.
50. Li, Y., P. McGowan, I. Hellstrom, K. E. Hellstrom, and L. Chen. 1994. Costimulation of tumor-reactive CD4 and CD8 T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol. 153:421.
51. Hersey, P., Z. Si, M. J. Smith, and M. D. Thomas. 1994. Expression of the co-stimulatory molecule B7 on melanoma cells. Int. J. Cancer 58:527.
52. Chen, P. W., V. K. Shreedhar, and H. N. Ananthaswamy. 1995. Rejection of murine melanoma cells transfected with the intercellular adhesion molecule 1 gene. Int. J. Oncol. 6:675.
53. Viaman, D., S. Pietrokovsky, B. Cohen, P. Benech, and J. Chebath. 1990. Synergism of type I and II interferons in stimulating the activity of the same DNA enhancer. FEBS Lett. 265:12.
54. Lewis, J. A., A. Huq, and B. Shan. 1989. Interferon-β and -γ both act synergistically to produce an antiviral state in cells resistant to both Interferons individually. J. Virol. 63:4560.
55. Czarniecki, C. W., C. W. Fennie, D. B. Pomers, and D. A. Estell. 1984. Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human interferons-α, -β and -γ. J. Virol. 49:490.
56. Oleszak, E., and W. E. Stewart II. 1985. Potentiation of the antiviral and anticellular activities of interferons by mixtures of human interferon-γ and -α or -β. J. Interferon Res. 5:361.
57. Kirkwood, J. M. 1995. Melanoma. In Biological Therapy of Cancer: Principles and Practice, 2nd Ed. V. T. Devita, S. Hellman, and S. A. Rosenberg, eds. J. B. Lippincott, Philadelphia, pp. 389-411.
58. Ernstoff, M. S., S. Nair, R. R. Bahnson, L. M. Miketic, B. Banner, W. Gooding, R. Day, T. Whiteside, T. Hakala, and J. M. Kirkwood. 1990. A phase I trial of sequential administration of recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 8:1637.
59. Ernstoff, M. S., W. Gooding, S. Nair, R. R. Bahnson, L. M. Miketic, B. Banner, R. Day, T. Whiteside, L. Titus-Ernstoff, and J. M. Kirkwood. 1992. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res. 52:851.